title: Diagnosis and the current trends in multiple myeloma therapy.
abstract: Multiple myeloma is still an incurable disease. In recent years the introduction of 3 novel drugs oriented on basic mechanisms of multiple myeloma cells proliferation and survival has improved patients' outcome. These drugs are: thalidomide, its new analog, lenalidomide, and proteasome inhibitor, bortezomib. All three are highly effective both in newly diagnosed and relapsed/resistant patients.
authors.affiliation: Department of Hematooncology and Bone Marrow Transplantation, Medical University, Lublin, Poland. annadmosz@o2.pl
authors.forename: Anna
authors.initials: A
authors.lastname: Dmoszyńska
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide